Google
Trusted Resources: News & Events
Latest announcements and gatherings
First Sickle Cell Patient Dosed in Phase 2a of IMR-687
This morning, Imara Inc. announced that it has dosed the first patient in its Phase 2a clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of escalating doses of IMR-687 in adult patients with sickle cell disease (SCD).
In May, IMR-687 was granted Rare Pediatric Disease designation by the U.S. Food and Drug Administration (FDA), the first SCD product candidate to receive the label. The drug is being developed as a highly-potent oral therapy for once-daily dosing with the intention of addressing both the underlying red and white blood cell pathologies associated with the condition.
SCD is a severe, hereditary variation of anemia in which a mutated form of hemoglobin distorts the red blood cells at low oxygen levels into crescent-shaped cells that resemble a sickle. “IMR-687 is being rapidly advanced, as Imara is dosing the first eligible patient less than 2 years from the launch of the company.
+myBinderRelated Content
-
Matthew Porteus awarded grant for sickle cell anemia workThe California Institute for Regenerativ...
-
Higher Prevalence of Hydroxyurea Use Is Associated with Lower Hospitalization Rate in a Population of Children with ...Background: Individuals with sickle cel...
-
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™Emmaus Life Sciences, Inc., a leader in ...
-
The first two years of life in sickle cell anemia infants: A results of a comprehensive longitudinal studyInfancy is a critical time during which ...
-
Stem cell gene-editing method may be breakthrough for sickle cell researchResearchers have cured mice with a genet...
-
Gene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
-
Calimmune Expands Lentiviral Gene Therapy Pipeline Through License of Sickle Cell Disease Therapeutic CandidateLicense of Gamma-Globin from Cincinnati ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
